FDA issues 7 observations on Dr. Reddy's plant

FDA issues 7 observations on Dr. Reddy's plant after inspecting its Hyderabad biologics facility, as noted in a new Form 483. This could delay approvals or trigger follow-up actions if not addressed promptly. While not a ban, it raises compliance concerns for the US-bound drugmaker. Seven observations signal moderate regulatory risk.

📊 STOCKS: DRREDDY | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #FDA